AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 22 min read$NKTR

HC Wainwright & Co. reiterates Buy rating on Nektar Therapeutics, $185 price target

HC Wainwright & Co. maintained a Buy rating on Nektar Therapeutics with a $185 price target, suggesting a 293.7% upside from the Oct 1 close of $46.99. The firm cited strong Phase 2b data for rezpeg and an undervalued stock as reasons for the recommendation.

Original reporting
tradingview.com
Published Oct 2, 2026, 11:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 11:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. reiterates Buy rating on Nektar Therapeutics, $185 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

$NKTRBullishMed
01

Why it matters

The upgrade could trigger buying pressure, especially among traders focused on biotech catalysts.

02

Market read

The new trial data and aggressive price target provide a fresh catalyst for NKTR, potentially moving the stock higher in the short term.

03

What to watch

Potential competition and regulatory timelines could dampen upside.

Relevance 8/10Novelty 8/10Timing: immediate

Background

Analyst note from HC Wainwright highlighting new Phase 2b data for rezpeg and issuing a $185 price target.

Company-level read

Ticker impact

$NKTRBullishHigh confidence
Context

HC Wainwright reiterated a Buy rating on Nektar Therapeutics and set a new $185 price target based on fresh Phase 2b REZOLVE-AA data.

Expected impact

likely upward pressure as investors price in the upgraded target and trial data.

Evidence & confidence

The combination of new efficacy data and a 293% upside target provides a clear catalyst for buying interest.

Market effects

Sector

Biotech sector may see renewed interest in oncology trials after positive Phase 2b results.

Regional

U.S. biotech investors could allocate more capital to NKTR and peers.

Global

Limited to investors tracking clinical-stage biotech pipelines.

Counterpoint

What could challenge this read

The Phase 2b data may not translate to Phase 3 success, making the $185 target overly optimistic.

Key entities

  • company
    Nektar Therapeutics

    Biopharma developing rezpeg for oncology.

  • analyst_firm
    HC Wainwright & Co.

    Equity research firm issuing the Buy rating.

Read at source← All news

Related articles

OCT 7
$NKTRLow

Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang

Nektar Therapeutics (NKTR) won a $115 million lawsuit against Eli Lilly (LLY), resolving a multi-year overhang. The verdict, including interest, amounts to ~5% of NKTR's market cap. Despite the win, NKTR's stock fell over $200 million in market cap due to market volatility and rising yields. Cedar Grove Capital Management views this as a net positive for NKTR, removing a long-standing uncertainty.

finance.yahoo.com2 min
OCT 1
$NKTRMedAI 8/10

NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge

Nektar Therapeutics (NKTR) shares fell 21% after reporting modest new response rates for its experimental skin drug, rezpegaldesleukin, in alopecia and eczema studies. Despite this, analysts at William Blair and Jefferies maintained bullish ratings, citing the drug's durability advantage. The company also faces an ongoing legal dispute with Eli Lilly.

newsable.asianetnews.com2 min
OCT 1
$NKTRMedAI 9/10

Nektar presents durable Phase 2b rezpegaldesleukin data; Phase 3 ZENITH AA starts early 2027

Nektar reported positive Phase 2b results for rezpegaldesleukin in alopecia areata and atopic dermatitis, showing durable responses. 31% of patients achieved SALT ≤20 after 52 weeks, with 63% maintaining it 6 months off treatment. Phase 3 trials, ZENITH AA and ZENITH AD, are planned to start in early 2027. According to the company, the data supports the drug's potential.

tradingview.com2 min